Sonoma Raises $265M to Advance Its T-cell Therapies

Sonoma Raises $265M to Advance Its T-cell Therapies

302187

Sonoma Raises $265M to Advance Its T-cell Therapies

Sonoma Biotherapeutics has raised $265 million in investment funding to support the development and production of novel immune T-cell therapies to treat severe autoimmune and inflammatory diseases, such as multiple sclerosis (MS). “We are ushering in a new era of medicine, using immune cells as living therapies that persist in the body, providing a lasting and potentially curative activity to treat autoimmune and inflammatory diseases,” Jeffrey Bluestone, PhD, co-founder and CEO of Sonoma, said in…

You must be logged in to read/download the full post.